the Start of Phase 1 Clinical Trials

Introduction

While often associated with large-scale Phase 3 trials, the Trial Master File (TMF) is just as critical during Phase 1. Regulatory agencies expect complete, current, and accessible documentation—even in early studies. The TMF tells the full story of a trial’s conduct, compliance, and oversight, and must be “inspection-ready at all times.” In this article, we explore what to include in your TMF from the earliest planning stages of a Phase 1 trial, who is responsible, and how to maintain quality and compliance throughout early development.

What Is the Trial Master File?

The TMF is a collection of essential documents that demonstrate compliance with Good Clinical Practice (GCP) and applicable regulatory requirements. These documents support the integrity of the trial and verify that the rights, safety, and well-being of participants have been protected.

Why Is TMF Important in Phase 1?

• Regulatory inspections: Phase 1 trials are often audited for first-in-human safety and consent practices
• Early deviations: Common in new compound protocols—require proper documentation
• Short timelines: Phase 1 trials can finish in weeks, leaving little time for cleanup
• Supports product lifecycle: TMF data is used in future filings and sponsor audits

Who Owns the TMF in Phase 1?

• Sponsor: Ultimately responsible for TMF oversight and completeness
• CRO (if involved): May maintain portions of the TMF, such as site files or monitoring reports
• Clinical Operations: Leads coordination of document flow
• Quality Assurance (QA): Reviews TMF for completeness and accuracy

Core TMF Sections to Include Early

1. Trial Management

• Trial protocol and all amendments
• Investigator’s Brochure (IB)
• Protocol synopsis and risk mitigation plan
• Trial design rationale and justification documents

2. Regulatory and Ethics Approvals

• Clinical Trial Authorization (CTA)/IND filing correspondence
• EC/IRB approvals and annual reviews
• Insurance certificates (if applicable)

3. Site Management

• Site selection documentation and qualification visit reports
• Delegation of Authority (DOA) logs
• Training records, CVs, GCP certificates for site staff
• Initiation visit reports and checklists

4. Subject Management

• Screening logs, enrollment logs
• Informed Consent Forms (ICFs) and AV recordings (where required)
• Eligibility checklists

5. Safety and Pharmacovigilance

• Adverse Event (AE) and Serious Adverse Event (SAE) forms
• Safety review meeting minutes (e.g., SRC or DSMB)
• Safety letter distribution logs

6. Monitoring and Oversight

• Monitoring plan and visit reports
• Deviation tracking logs
• Trip reports and follow-up letters

7. Data Management

• Data Management Plan (DMP)
• Electronic Data Capture (EDC) access logs
• Data query logs and CRF completion guidelines

8. Investigational Product (IP)

• Drug shipment records, temperature logs
• Accountability logs, destruction certificates
• Randomization lists (blinded/unblinded version control)

eTMF vs. Paper TMF in Phase 1

Most sponsors now use electronic Trial Master File (eTMF) platforms, even for early-phase studies. Benefits include:

• Real-time visibility and audit trails
• Faster document indexing and versioning
• Better collaboration across global teams

Examples of popular eTMF systems: Veeva Vault, MasterControl, PhlexTMF, Wingspan, and OpenText.

Inspection Readiness Tips

• Ensure real-time filing rather than “file in bulk” approaches
• Use document trackers to follow up on missing or overdue files
• Audit TMF at key milestones: FIH dose, cohort completion, close-out
• Train study staff on the TMF structure and roles
• Back up key source documents and correspondence routinely

Common Mistakes in Phase 1 TMFs

• Missing delegation logs or staff CVs
• Incomplete SAE follow-up reports
• Unapproved ICF versions still in use
• Protocol deviations undocumented or not categorized

Regulatory Expectations

FDA

• Expects TMF to support audit trails and GCP compliance under 21 CFR Part 312
• May inspect TMF in sponsor or CRO office even during Phase 1

EMA

• TMF requirements defined in ICH E6(R2) and EU Directive 2005/28/EC
• Inspection readiness applies at all times

CDSCO (India)

• Includes TMF review in GCP audits and Bioavailability/Bioequivalence inspections
• Requires AV consent records for FIH trials as part of TMF

Best Practices for TMF Setup in Phase 1

• Initiate TMF creation at protocol finalization
• Define roles and access permissions early
• Use a TMF plan and file structure based on the DIA TMF Reference Model
• Implement quality review checkpoints and version control systems
• Archive appropriately after trial closeout—minimum 15 years retention